{'fraction_non_alphanumeric': 0.028119507908611598, 'fraction_numerical': 0.0017574692442882249, 'mean_word_length': 5.820359281437126, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Efficacy of Silibinin to Reduce the Impact of Obesity on Invasive Prostate Cancer

Obesity is a risk factor for therapeutic resistance, disease progression, and metastasis in prostate cancer (PCa) patients. Further, obesity results in a state of chronic inflammation, which has been linked, to several types of cancer including the prostate. Previously, we have shown that obesity‐related systemic factors promoted an invasive prostate cancer phenotype, in vitro. Specifically, interleukin‐6 (IL‐6) has been identified as a pro‐inflammatory cytokine, which may mediate obesity‐induced prostate cancer progression. Interestingly, silibinin, a polyphenol found in milk thistle seed, reduces inflammation and may have anti‐tumorigenic properties. The mechanisms involved in obesity‐induced PCa progression are not completely understood, therefore limiting the development of effective interventions to inhibit or reverse the tumor promoting effects of obesity. Therefore, we hypothesize that silibinin may be used to reduce or reverse the impact of obesity on invasive prostate cancer by using an in vitro approach of obesity and cancer.